Show metadata Hide metadata

(19)

(11)

2 761 457

(13)

(51)

IPC

A61K31/4155(2006-01-01)

A61K31/427(2006-01-01)

A61K31/4439(2006-01-01)

A61K31/506(2006-01-01)

A61P35/00(2006-01-01)

A61P35/02(2006-01-01)

A61P37/00(2006-01-01)

A61P43/00(2006-01-01)

C07D401/04(2006-01-01)

C07D403/04(2006-01-01)

C07D403/14(2006-01-01)

C07D417/04(2006-01-01)

(21) (22)

Application

2019127038, 2018-01-30

(24)

Start date

2018-01-30

(22)

Actual filing date

2018-01-30

(45)

Published

2021-12-08

(72)

Inventor

Li, DansuSnir-Alkalaj, IritVakka, JozefBen Neriakh, JinonVenkatak-Ialam, Avantika

(73)

Holder

Jissum Riserch Divelopment Kompani Of Dze Khebryu Yuniversiti Of Ierusalim Ltd.

N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER Russian patent published in 2021 - IPC A61K31/4155 A61K31/427 A61K31/4439 A61K31/506 A61P35/00 A61P35/02 A61P37/00 A61P43/00 C07D401/04 C07D403/04 C07D403/14 C07D417/04

Abstract RU 2761457 C2

FIELD: medicine.

SUBSTANCE: present invention provides for pyrazole derivatives of the formula (I) and, in particular, N1-(4-(5-(cyclopropylmethyl)-1-methyl-1h-pyrazole-4-yl)pyridine-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as inhibitors of casein kinase 1 (hereinafter – CK1) and/or interleukin-1-associated kinase-1 receptor (hereinafter – IRAK1) for the treatment of cancer, inflammatory and immune-mediated disorders.

EFFECT: obtaining N1-(4-(5-(cyclopropylmethyl)-1-methyl-1h-pyrazole-4-yl)pyridine-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as inhibitors of CK1 and/or IRAK1 for the treatment of cancer.

30 cl, 8 ex, 1 tbl, 1 dwg

Similar patents RU2761457C2

Title	Year	Author	Number
PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF	2016	Ben Neriah Yinon Brachya Guy Burstain Ido Minzel Waleed Snir-Alkalay Irit Vacca Joseph Li Dansu	RU2735522C2
(ALPHA-SUBSTITUTED ARALKYLAMINO- AND HETEROARYLALKYLAMINO)PYRIMIDINYL- AND 1,3,5-TRIAZINYLBENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF IN TREATING PROLIFERATIVE DISEASES	2012	Braun S. Devid Mettyuz Devid Dzh.	RU2608742C2
5,5-CONDENSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS	2010	Dusson Siril B. Djukan David Parsi Kristof Klod P'Erra Kler Aleksandr Fransua-Rene Brand Gijom Da Kosta Daniel' Raali Usin Paparehn Zhan-Loran Derok Mishel' Konvar T'Erri Sjurlero Dominik	RU2554087C2
BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR TREATING CANCER	2015	Long, Yun	RU2741914C2
ARYLSULPHONAMIDE CCR3 ANTAGONISTS	2010	Laj Taj Vehj Forrester Dzhared Ehndrju	RU2539591C2
2,5-DISUBSTITUTED ARYLSULPHONAMIDE CCR3 ANTAGONISTS	2010	Laj Taj Vehj Tran Mari Shantal' S'Ju-Jing Baaum Ehrik Din	RU2532515C2
PRODRUGS OF OPIOID RECEPTOR ANTAGONISTS	2018	Shakh, Nikezh Tusche, Majkl V. Dzhi, Liangliang Ding, Mingping Khan, Tsyan	RU2785777C2
PYRAZOLPYRIMIDINE COMPOUNDS JAK INHIBITORS AND METHODS	2009	Blehjni Dzheffri Gibbons Pol A. Khanan Ehmili Lissikatos Dzhozef P. Magnuson Stiven R. Pastor Richard Rouson Tomas E. Chzhou Ajkheh Chzhu Bin-Jan'	RU2539568C2
TREATING CONDITIONS ASSOCIATED WITH HYPERINSULINEMIA	2015	Landau Steven B. Kagey Michael	RU2722179C2
3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND VARIANTS OF THEIR USE	2018	Beckwith, Rohan Eric John Bonazzi, Simone Cernijenko, Artiom Fazal, Aleem Tichkule, Ritesh Bhanudasji Visser, Michael Scott	RU2795850C2

RU 2 761 457 C2

Authors

Li, Dansu

Snir-Alkalaj, Irit

Vakka, Jozef

Ben Neriakh, Jinon

Venkatak-Ialam, Avantika

Dates

2021-12-08—Published

2018-01-30—Filed